Cargando…

Antituberculosis Drugs (Rifampicin and Isoniazid) Induce Liver Injury by Regulating NLRP3 Inflammasomes

Patients being treated for pulmonary tuberculosis often suffer liver injury due to the effects of anti-TB drugs, and the underlying mechanisms for those injuries need to be clarified. In this study, rats and hepatic cells were administrated isoniazid (INH) and rifampin (RIF) and then treated with NL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Su, Qiang, Kuang, Wei, Hao, Weiyi, Liang, Jing, Wu, Liang, Tang, Chunmei, Wang, Yali, Liu, Tao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914095/ https://www.ncbi.nlm.nih.gov/pubmed/33688304 http://dx.doi.org/10.1155/2021/8086253

Ejemplares similares

Study on the associations between liver damage and antituberculosis drug rifampicin and relative metabolic enzyme gene polymorphisms
por: Su, Qiang, et al.
Publicado: (2021)

Fatal poisoning by isoniazid and rifampicin
por: Sridhar, A., et al.
Publicado: (2012)

Isoniazid- and rifampicin-induced thrombocytopenia
por: Yakar, Fatih, et al.
Publicado: (2013)

Naringenin protects against isoniazid- and rifampicin-induced apoptosis in hepatic injury
por: Wang, Chao, et al.
Publicado: (2016)

Hepatoprotective activity of melittin on isoniazid- and rifampicin-induced liver injuries in male albino rats
por: Naji, Khalid Mohammed, et al.
Publicado: (2021)

Microencapsulated Isoniazid-Loaded Metal–Organic Frameworks for Pulmonary Administration of Antituberculosis Drugs
por: Fernández-Paz, Cristina, et al.
Publicado: (2021)

Mitochondrial Damage and Drp1 Overexpression in Rifampicin- and Isoniazid-induced Liver Injury Cell Model
por: Li, Fangfang, et al.
Publicado: (2019)

Mechanisms of isoniazid and rifampicin-induced liver injury and the effects of natural medicinal ingredients: A review
por: Zhuang, Xiuping, et al.
Publicado: (2022)

Effectiveness of ellagic acid on isoniazid-rifampicin induced liver damage in rats
por: Ambrose, Samuel Stephen, et al.
Publicado: (2013)

Hepatoprotective Activity of Heptoplus on Isoniazid and Rifampicin Induced Liver Damage in Rats
por: Sankar, M., et al.
Publicado: (2015)

Antituberculosis Drug-Induced Hepatotoxicity in IranianTuberculosis Patients: Role of Isoniazid Metabolic Polymorphism
por: Sistanizad, Mohammad, et al.
Publicado: (2011)

Treating More with Less: Effectiveness and Event Outcomes of Antituberculosis Fixed-dose Combination Drug versus Separate-drug Formulation (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide) for Pulmonary Tuberculosis Patients in Real-world Clinical Practice
por: Lai, Jacqueline Mui Lan, et al.
Publicado: (2019)

Effect of rifampicin & isoniazid on the steady state pharmacokinetics of moxifloxacin
por: Ramachandran, Geetha, et al.
Publicado: (2012)

Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children
por: Mukherjee, Aparna, et al.
Publicado: (2015)

Intrapatient variability in plasma rifampicin & isoniazid in tuberculosis patients
por: Kumar, A. K. Hemanth, et al.
Publicado: (2018)

Clofazimine, but Not Isoniazid or Rifampicin, Augments Platelet Activation in vitro
por: Anderson, Ronald, et al.
Publicado: (2018)

NLRP3 inflammasome activation mechanism and its role in autoimmune liver disease: Role of NLRP3 inflammasome in autoimmune liver disease
por: Guan, Yanling, et al.
Publicado: (2022)

N-Acetyltransferase 2 Genotypes among Zulu-Speaking South Africans and Isoniazid and N-Acetyl-Isoniazid Pharmacokinetics during Antituberculosis Treatment
por: Mthiyane, Thuli, et al.
Publicado: (2020)

Protective Effects of Metallothionein on Isoniazid and Rifampicin-Induced Hepatotoxicity in Mice
por: Lian, Yong, et al.
Publicado: (2013)

Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India
por: Aruldhas, Blessed Winston, et al.
Publicado: (2019)

The Variant at TGFBRAP1 but Not TGFBR2 Is Associated with Antituberculosis Drug-Induced Liver Injury
por: Zhang, Jingwei, et al.
Publicado: (2019)

Synthesis, characterization, and efficacy of antituberculosis isoniazid zinc aluminum-layered double hydroxide based nanocomposites
por: Saifullah, Bullo, et al.
Publicado: (2016)

Adequacy of the 10 mg/kg Daily Dose of Antituberculosis Drug Isoniazid in Infants under 6 Months of Age
por: López-Ramos, Maria Goretti, et al.
Publicado: (2023)

Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co–therapy
por: Li, Feng, et al.
Publicado: (2013)

Simultaneous Spectrophotometric Determination of Rifampicin, Isoniazid and Pyrazinamide in a Single Step
por: Asadpour-Zeynali, Karim, et al.
Publicado: (2016)

Toxicoproteomic Profiling of hPXR Transgenic Mice Treated with Rifampicin and Isoniazid
por: Brewer, Christopher Trent, et al.
Publicado: (2020)

Rifampicin and isoniazid drug resistance among patients diagnosed with pulmonary tuberculosis in southwestern Uganda
por: Micheni, Lisa Nkatha, et al.
Publicado: (2021)

The Role of Autophagy and NLRP3 Inflammasome in Liver Fibrosis
por: Tao, Ye, et al.
Publicado: (2020)

The NLRP3 inflammasome in viral infection (Review)
por: Zheng, Qiaoli, et al.
Publicado: (2023)

Use of DNA microarray chips for the rapid detection of Mycobacterium tuberculosis resistance to rifampicin and isoniazid
por: Tang, Peijun, et al.
Publicado: (2017)

Incidence and Temporal Trend of Antituberculosis Drug-Induced Liver Injury: A Systematic Review and Meta-Analysis
por: Wang, Nannan, et al.
Publicado: (2022)

The perceived impact of isoniazid resistance on outcome of first-line rifampicin-throughout regimens is largely due to missed rifampicin resistance
por: Van Deun, Armand, et al.
Publicado: (2020)

Heteroresistance to rifampicin & isoniazid in clinical samples of patients with presumptive drug-resistant tuberculosis in Central India
por: Desikan, Prabha, et al.
Publicado: (2023)

Isoniazid, Pyrazinamide and Rifampicin Content Variation in Split Fixed-Dose Combination Tablets
por: Pouplin, Thomas, et al.
Publicado: (2014)

Low isoniazid and rifampicin concentrations in TB/HIV co-infected patients in Uganda
por: Sekaggya Wiltshire, Christine, et al.
Publicado: (2014)

Development and In Vitro Release of Isoniazid and Rifampicin-Loaded Bovine Serum Albumin Nanoparticles
por: Ge, Zhaohui, et al.
Publicado: (2018)

A Lower Dose of Efavirenz Can Be Coadministered With Rifampicin and Isoniazid in Tuberculosis Patients
por: Kaboggoza, Julian P, et al.
Publicado: (2019)

Isoniazid and Rifampicin Produce Hepatic Fibrosis through an Oxidative Stress-Dependent Mechanism
por: Biswas, Ayan, et al.
Publicado: (2020)

Improved Stability of Rifampicin in the Presence of Gastric-Resistant Isoniazid Microspheres in Acidic Media
por: Mwila, Chiluba, et al.
Publicado: (2020)

Diagnostic performance of DNA microarray for detecting rifampicin and isoniazid resistance in Mycobacterium tuberculosis
por: Sun, Bingqi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kt3uj157o8555b76cqeplcnbpj